|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berg J: Canine osteosarcoma: amputation
and chemotherapy. Vet Clin North Am Small Anim Pract. 26:111–121.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Q, Wang C, Zhu J, et al:
RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth,
invasion and migration of SaOS2 human osteosarcoma cells: a case
control study. J Exp Clin Cancer Res. 30:262011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Si H, Peng C, Li J, et al: RNAi-mediated
knockdown of ERK1/2 inhibits cell proliferation and invasion and
increases chemosensitivity to cisplatin in human osteosarcoma U2-OS
cells in vitro. Int J Oncol. 40:1291–1297. 2012.PubMed/NCBI
|
|
5
|
Ma JF, Liu L, Yang WJ, et al:
RNAi-mediated knockdown of relaxin decreases in vitro proliferation
and invasiveness of osteosarcoma MG-63 cells by inhibition of
MMP-9. Eur Rev Med Pharmacol Sci. 17:1102–1109. 2013.PubMed/NCBI
|
|
6
|
Martin JW, Zielenska M, Stein GS, et al:
The role of runx2 in osteosarcoma oncogenesis. Sarcoma.
2011:2827452011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sadikovic B, Thorner P, Chilton-Macneill
S, et al: Expression analysis of genes associated with human
osteosarcoma tumors shows correlation of RUNX2 overexpression with
poor response to chemotherapy. BMC Cancer. 10:2022010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pereira BP, Zhou Y, Gupta A, et al: Runx2,
p53 and pRB status as diagnostic parameters for deregulation of
osteoblast growth and differentiation in a new pre-chemotherapeutic
osteosarcoma cell line (OS1). J Cell Physiol. 221:778–788. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nathan SS, Pereira BP, Zhou YF, et al:
Elevated expression of Runx2 as a key parameter in the etiology of
osteosarcoma. Mol Biol Rep. 36:153–158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding M, Lu Y, Abbassi S, et al: Targeting
Runx2 expression in hypertrophic chondrocytes impairs endochondral
ossification during early skeletal development. J Cell Physio.
227:3446–3456. 2012. View Article : Google Scholar
|
|
11
|
Lucero CM, Vega OA, Osorio MM, et al: The
cancer-related transcription factor runx2 modulates cell
proliferation in human osteosarcoma cell lines. J Cell Physiol.
228:714–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Won KY, Park HR and Park YK: Prognostic
implication of immunohistochemical Runx2 expression in
osteosarcoma. Tumori. 95:311–316. 2009.PubMed/NCBI
|
|
13
|
Yun SJ, Yoon HY, Bae SC, et al:
Transcriptional repression of RUNX2 is associated with aggressive
clinicopathological outcomes, whereas nuclear location of the
protein is related to metastasis in prostate cancer. Prostate
Cancer Prostatic Dis. 15:369–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niu DF, Kondo T, Nakazawa T, et al:
Transcription factor Runx2 is a regulator of epithelial-mesenchymal
transition and invasion in thyroid carcinomas. Lab Invest.
92:1181–1190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dalle CL, Frigo A, Francia G, et al: Runx2
m RNA expression in the tissue, serum and circulating
non-hematopoietic cells of patients with thyroid cancer. J Clin
Endocrinol Metab. 97:E1249–E1256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mishra S, Vaughn AD, Devore DI, et al:
Delivery of si RNA silencing Runx2 using a multifunctional
polymer-lipid nanoparticle inhibits osteogenesis in a cell culture
model of heterotopic ossification. Integr Biol (Camb). 4:1498–1507.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu J, Yu J, Rhodes DR, et al: A polycomb
repression signature in metastatic prostate cancer predicts cancer
outcome. Cancer Res. 67:10657–10663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Merten OW: Advances in cell culture:
anchorage dependence. Philos Trans R Soc Lond B Biol Sci.
370:201400402015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borowicz S, Van Scoyk M, Avasarala S, et
al: The soft agar colony formation assay. J Vis Exp.
e519982014.PubMed/NCBI
|
|
20
|
Marshall J: Transwell ® invasion assays.
Methods Mol Biol. 769:97–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duffy MJ, Mc Gowan PM and Gallagher WM:
Cancer invasion and metastasis: changing views. J Pathol.
214:283–293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yancopoulos GD: Clinical application of
therapies targeting VEGF. Cell. 143:13–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pei Y, Harvey A, Yu XP, et al:
Differential regulation of cytokine-induced MMP −1 and MMP −13
expression by p38 kinase inhibitors in human chondrosarcoma cells:
potential role of Runx2 in mediating p38 effects. Osteoarthritis
Cartilage. 14:749–758. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirata M, Kugimiya F, Fukai A, et al: C/
EBQ ᵝ and RUNX2 cooperate to degrade cartilage with MMP −13 as the
target and HIF-2α as the inducer in chondrocytes. Hum Mol Genet.
21:1111–1123. 2012. View Article : Google Scholar : PubMed/NCBI
|
